INFLUENCE OF AUTOANTIBODIES PROFILE ON DISEASE ACTIVITY MEASUREMENT IN A COLOMBIAN COHORT OF RHEUMATOID ARTHRITIS PATIENTS

J.B. Florez, G. Quintana, P. Mendez, P. Coral, on behalf of Reumavance Group.
Department of Rheumatology, Fundacion Santa Fe de Bogotá University Hospital, Bogotá, Colombia. Rheumatology, Fundacion Santa Fe de Bogotá, Bogotá DC, Colombia

Background: Traditionally, the role of Rheumatoid Factor (RF) and/or Anti-citrullinated antibodies (ACCP) presence have characterised for diagnosis and prognosis of Rheumatoid Arthritis (RA). However, Anti-nuclear antibodies (ANA) are not routinely measured for the diagnosis of the disease or RA prognosis establishment during first appointment. Recently, evidence showed that positive ANA titles could be considered as poor prognosis factor for RA, and also a higher probability of developing immunogenicity against biologic therapies.

Objectives: To compare the disease activity measurement from a Colombian cohort of patients with RA, based on their auto-antibodies profile.

Methods: The study used a cohort of Colombian patients with RA. A database was developed using the information from the clinical records. The data included: RF, ACCP, ANA, and the disease activity measured using DAS-28 ESR. Disease activity results were obtained in the following periods of time: 0, 3, 12, 24 and 36 months. Patients were classified based on the different autoantibody profiles (RF/ACCP/ANA: −, +, ++, +++, −+, +−). Mean DAS-28 ESR results from each period of time were calculated. Also mean weekly Methotrexate (MTX) dose was calculated for each profile. Mean differences between initial, and the follow-up period were calculated using Kruskal-Wallis test. Statistical analysis was made using STATA 12.0 software.

Results: 635 patients with RA were included. 32% of them were men, and 68% were women. Mean age was 54.3 years. The most prevalent profile was ++ with 118 patients, and the less frequent was −++. Patients with −++ profile had the best response to treatment over time, but also they required more MTX dose. Less response during time was observed with − profile, however the amount of patients from these group was relatively low. As it was expected, − profile patients required less weekly MTX dose (9.26 mg). It was interesting that patients with − profile present a worst outcome based on DAS-28 activity, and less response to the treatment.

Conclusions: Results from the study suggest the importance of including the measurement of ANA titles in the initial categorization and follow-up of patients with RA. The presence of ANA seems to have a worst prognosis. ANA co-existence with ACCP appear to have a worst outcome, compared to ++ or −++ profile. Auto-antibody profile in RA could direct the best therapeutic strategy for each patient. Validation of these results are required based on other cohorts.

REFERENCE:

Disclosure of Interest: None declared
Several serological biomarkers were measured in each cohort, selected due to the specific tissue metabolite they represent. These included: C2M (cartilage degradation); CTX-I and PINP (bone resorption and formation); C1M and C3M (interstitial matrix degradation); CRPM (CRP metabolite) and VICM (macrophage activity).

Each biomarker was log transformed and min-max normalised in order to allow for direct comparison of each of the variables. Patient clustering was performed using Ward hierarchical clustering and the number of clusters determined using the GAP statistic. ANOVA test was used to identify differences in delta change in radiographic scores at 24 and 52 weeks in the RA placebo groups (n=271) only.

**Results:** Clustering analysis resulted in five different clusters (A-E). Cluster A and B were both comprised of >98% RA patients. Cluster D was comprised mainly of OA patients whilst clusters C and E were a mix of OA and RA patients.

Clusters A and B were characterised by high levels of all biomarkers compared to other clusters except for VICM, which is significantly lower in cluster A than in cluster B (Tukey test p<0.001). Biomarker levels in Cluster C were all close to the median. Cluster D was characterised by low levels of all biomarkers compared to other clusters with significantly lower C2M levels, whilst cluster E also had low levels of markers, yet with significantly higher levels of CTX-I compared to cluster D. When looking at the RA placebo groups there were no difference in change in SHP score at 24 weeks between the groups, (n=271, LITHE, OSKIRA), but a significant difference in SHP change 52 weeks (p=0.03, LITHE).

**Objectives:** The aim of this study was to determine whether ACPA associate with changes in BMD over time in patients with RA.

**Methods:** Yearly dual x-ray absorbometry (DXA) scans were performed during 5 years of follow-up in 412 patients with recent-onset RA participating in the IMPROVED study 1, a clinical trial in which patients were treated according to a remission- (disease activity score <1.6) steered strategy. The effect of the presence of ACPA on 1) Z-scores of lumbar spine and hip over time, and 2) prevalence of osteopenia/osteoporosis (defined as a T-score ≤−1) over time was analysed using generalised estimating equations. Analyses were adjusted for age, gender, BMI, symptom duration, smoking status, disease activity, prednisone intake, usage of bisphosphonates, calcium intake and serum 25-OH vitamin D levels.

**Results:** ACPA-positive patients had a significantly lower lumbar spine (p=0.04) and hip (p=0.01) Z-score at baseline. There was no difference in prevalence of osteoporosis/osteopenia at baseline between ACPA-positive and ACPA-negative patients (OR (95% CI) 1.02 (0.55 to 1.91)). We hypothesised that ACPA-positive patients would have more BMD loss over time compared to ACPA-negative patients. However, ACPA-positivity did not associate with a stronger decline in Z-score over time at lumbar (p=0.43) or femoral sites (p=0.67). Additionally, no effect of ACPA-positivity was found on the development of osteoporosis/osteopenia over time (p=0.23).

**Conclusions:** ACPA-positive patients have a significantly lower baseline BMD compared to ACPA-negative patients. Surprisingly, ACPA do not associate with a decrease in BMD over time in patients who were treated according to a tight control strategy. These results indicate that ACPA alone do not contribute to bone loss after disease onset in the absence of inflammation/disease activity.

**REFERENCE:**

**Disclosure of Interest:** None declared

**ABO252**

**LOOSING DAS28-ESR, BUT STAYING IN BOOLEAN REMISSION- IS IT POSSIBLE? DATA FROM THE PROSPECTIVE, RANDOMISED RETRO TRIAL ON RHEUMATOID ARTHRITIS PATIENTS IN STABLE REMISSION**

J. Erhard1, M. Hagen1, M. Engbrecht1, J. Haschka2, M. Reiser3, A. Kleyer1, A. J. Hueber1, B. Manger1, C. Figueiredo3, J. F. Coobra3, H.-P. Tony4, S. Finzel5, N. Schett1, J. Reich1, R. Alten14, J. Henes15, K. Krueger16, G. Schett1, J. Reich1. 1Department of Internal Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-nuremberg, Erlangen, Germany; 2St. Vincent Hospital, Vincenzo Study Group, Medical University Vienna, Vienna, Austria; 3Instituto de Rheumatologia, Sao Paolo, Brazil; 4University of Wuerzburg, Internal Medicine 2, Wuerzburg; 5University Medical Center Freiburg, Rheumatology and Clinical Immunology, Freiburg; 6Rheumatology Clinical Practice, Rheumatology Clinical Practice Erlangen, Erlangen; 7Rheumatology Practice and Department of Internal Medicine 2, Clinic Burghasen, Burghasen; 8Department of Rheumatology and Clinical Immunology, Asklepios Medical Center, Bad Abbach; 9Rheumatology Practice Bamberg, Bamberg; 10Rheumatology Practice Bayreuth, Bayreuth; 11University of Heidelberg, Medicine 5, Heidelberg; 12Rheumatology Practice Nuernberg, Nuernberg; 13Schlosspark Klinik, Internal Medicine/Rheumatology, Berlin; 14University of Tuebingen, Centre for Interdisciplinary Clinical Immunology, Tuebingen; 15Praxizentrum St. Bonifatius, Munich, Germany

**Background:** DAS28-ESR is the most widely used instrument to assess remission in rheumatoid arthritis (RA) patients. Nonetheless, substantial residual disease activity can be present in RA patients fulfilling DAS28-ESR remission. Therefore, more stringent criteria for remission have been developed. While it is known that patients can fulfil DAS28-ESR but fail ACR/EULAR Boolean remission criteria, the existence of the reverse is less known.

**Objectives:** To test the possibility to loose DAS28-ESR remission while staying in ACR/EULAR remission in patients with RA.

**Methods:** Data were obtained from the prospective randomised RETRO study. (EudraCT: 2009–015740–42), which recruits RA patients in stable remission. Remission was assessed by the following instruments every three months: DAS28-ESR, DAS28-CRP, CDAI, SDAI, PAS, and ACR/EULAR criteria. In the group of patients, escaping DAS28-ESR remission, but fulfilling ACR/EULAR Boolean remission, the individual components of DAS28-ESR were analysed that determined their escape from remission.

**Results:** 142 patients analysed, which were all in DAS28-ESR remission at baseline. Of them, 140 (98.59%) were in DAS-CRP-remission, 131 (92.25%) in CDAI-remission, 130 (91.55%) in SDAI-remission, 109 (76.76%) in ACR/EULAR remission and 66 (46.48%) in PAS-remission. We analysed upon the 1 year follow up usage of bisphosphonates, calcium intake and serum 25-OH vitamin D levels.

**Disclosure of Interest:** None declared